Madrigal’s Rezdiffra Continues Its Solid Launch

26 Feb 2025

With $180m in sales during its first nine months on the US market, the first approved MASH drug still tops projections. Madrigal predicts continued growth in 2025, with EU entry expected.

Set of Three Increasing Size Red and White Cartoon Spaceships on Dark Background — Madrigal's Rezdiffra continued its early growth through three quarters on the market • Source: Alamy

Madrigal’s successful launch of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom) continued during the fourth quarter and on 26 February the company predicted strong year-over-year sales growth for 2025, driven partially by expected EU approval and initial launch in Germany later this year.

Key Takeaways

Madrigal continues to beat Wall Street projections for the launch of Rezdiffra, the first approved MASH drug.

The Conshohocken, PA-based company also reported two-year data from a cohort of MASH patients with cirrhosis from an ongoing study,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

PTC Projects Confidence In Sephience Launch With Royalty Buyback

08 Aug 2025

• By Manas Mishra

The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

07 Aug 2025

• By Mandy Jackson

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

07 Aug 2025

• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

Korea Q2 Roundup: Global Sales, License Income Boost Yuhan, GC

07 Aug 2025

• By Jung Won Shin

Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA)

06 Aug 2025

• By Alaric DeArment

The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.